

JUL 10 2003

EXPRESS MAIL NO. EL852691555US

PTO/SB/08B (05-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**Complete if Known****INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Application Number**

09/875,440

**Filing Date**

June 5, 2001

**First Named Inventor**

Christoph Reinhard

**Art Unit**

1635

**Examiner Name**

Sean McGarry

Sheet

1

of

1

Attorney Docket Number

59516-149/PP-01701.002

RECEIVED  
JUL 22 2003  
TECH CENTER 1600/2900**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
M		MASOOD, R. ET AL., <i>Malignant Mesothelioma Growth Inhibition by Agents that Target the VEGF and VEGF-C Autocrine Loops</i> , INT. J. CANCER, 104:603-610, 2003	
H		POMERANTZ, R. G. ET AL., <i>The Role of Epidermal Growth Factor Receptor in Head and Neck Squamous Cell Carcinoma</i> , CURR. ONCOL. REP., 5:140-146, 2003	
H		STEARNS, M. E. ET AL., <i>Interleukin 10 Blocks Matrix Metalloproteinase-2 and Membrane Type 1-Matri Metalloproteinase Synthesis in Primary Human Prostate Tumor Lines</i> , CLIN. CAN. RES., 9:1191-1199, 2003	
M		NAOR, D. ET AL., <i>CD44 in Cancer</i> , CRIT. REV. CLIN. LAB. SCI., 39:527-579, 2002	
H		BURCHERT, A. ET AL., <i>CD82 (KAI1), A Member of the Tetraspan Family, is Expressed on Early Haemopoietic Progenitor Cells and Up-Regulated in Distinct Human Leukemias</i> , BRIT. JOUR. HAEMATOL., 107: 494-504, 1999	
M		TACHIBANA, I. ET AL., <i>NAG-2, A Novel Transmembrane-4 Superfamily (TM4SF) Protein that Complexes with Integrins and Other TM4SF Proteins</i> , J. BIOL. CHEM., 272:29181-29189, 1997	
R		OREN, R. ET AL., <i>TAPA-1, The Target of an Antiproliferative Antibody, Defines a New Family of Transmembrane Proteins</i> , MOL. CELL. BIOL., 10:4007-4015, 1990	

Examiner Signature	Date Considered
	12/10/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.